Castle Biosciences Inc
CSTL
Services-Medical Laboratories
Mkt Cap
$674.2MPE
-21.89Debt
$10.2MCash
$82.95MEV
$601.5MFCF
-$6.457MP/E Ratio
-21.89Debt
$10.2MCash
$82.95MEV
$601.5MFCF
-$6.457MCharts data: {"Earnings":[{"time":"2018-12-30","value":-10163000},{"time":"2019-12-30","value":2991000},{"time":"2020-12-30","value":-10284000},{"time":"2021-12-30","value":-31292000},{"time":"2022-12-30","value":-67138000},{"time":"2023-12-30","value":-57466000}],"Sales":[{"time":"2018-12-30","value":22786000},{"time":"2019-12-30","value":51865000},{"time":"2020-12-30","value":62649000},{"time":"2021-12-30","value":94085000},{"time":"2022-12-30","value":137039000},{"time":"2023-12-30","value":219788000}],"Net Margins":[{"time":"2018-12-30","value":-0.4460194856490828},{"time":"2019-12-30","value":0.057668948230984285},{"time":"2020-12-30","value":-0.16415266005842072},{"time":"2021-12-30","value":-0.3325928681511399},{"time":"2022-12-30","value":-0.48991892818832594},{"time":"2023-12-30","value":-0.2614610442790325}],"Assets":[{"time":"2018-12-30","value":22404935},{"time":"2019-12-30","value":119746000},{"time":"2020-12-30","value":439328000},{"time":"2021-12-30","value":462572000},{"time":"2022-12-30","value":447329000},{"time":"2023-12-30","value":453340000}],"Stockholders Equity":[{"time":"2018-12-30","value":-56565302},{"time":"2019-12-30","value":85113000},{"time":"2020-12-30","value":415691000},{"time":"2021-12-30","value":411740000},{"time":"2022-12-30","value":399150000},{"time":"2023-12-30","value":391269000}],"ROE":[{"time":"2018-12-30","value":0.17966844762890155},{"time":"2019-12-30","value":0.03514151774699517},{"time":"2020-12-30","value":-0.024739530083643862},{"time":"2021-12-30","value":-0.07599941710788362},{"time":"2022-12-30","value":-0.16820243016409872},{"time":"2023-12-30","value":-0.1468708228865563}],"ROA":[{"time":"2018-12-30","value":-0.17121227979460776},{"time":"2019-12-30","value":0.082842015599686},{"time":"2020-12-30","value":-0.014890924320780829},{"time":"2021-12-30","value":-0.08649680482173586},{"time":"2022-12-30","value":-0.15399627567182098},{"time":"2023-12-30","value":-0.12651431596594168}]}
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
![LH Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>LH</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth 160%
Earnings Stability -53%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|
| Net Margin | -45% | 5.8% | -16% | -33% | -49% | -26% | -12% |
| ROA | -17% | 8.3% | -1.5% | -8.6% | -15% | -13% | -6.7% |
| ROE | 18% | 3.5% | -2.5% | -7.6% | -17% | -15% | -7.7% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -27.27%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -2.54%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -7.84%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -1.6%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -3.35%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -6.55%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | 5.35 | 0.00 | - | - | 0.00 | -1.58 | |||
| Debt Equity | -0.43 | 0.38 | 0.00 | - | - | 0.00 | 0.03 | |||
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | |||
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -1.58.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -1.03.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|
| Revenue | 57% | 52% | 60% | -11% |
| Net Income | - | - | - | - |
| Stockholders Equity | - | -2% | -2% | -120% |
| FCF | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +57.35%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -10.96%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +41.41%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is -.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -117.32%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is +8.89%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.